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Background. Traditional methods for identifying comorbidity data in EMRs have relied primarily on costly and time-consuming
manual chart review. The purpose of this study was to validate a strategy of electronically searching EMR data to identify
comorbidities among cancer patients. Methods. Advanced stage NSCLC patients (N = 2,513) who received chemotherapy from
7/1/2006to6/30/2008wereidentiﬁed usingiKnowMed,USOncology’sproprietaryoncology-speciﬁcEMRsystem.EMRdatawere
searched for documentation of comorbidities common to advanced stage cancer patients. The search was conducted by a series
of programmatic queries on standardized information including concomitant illnesses, patient history, review of systems, and
diagnoses other than cancer. The validity of the comorbidity information that we derived from the EMR search was compared
to the chart review gold standard in a random sample of 450 patients for whom the EMR search yielded no indication of
comorbidities.Negative predictive values werecalculated. Results.The overallprevalence ofcomorbiditiesof22%.Overallnegative
predictive value was 0.92 in the 450 patients randomly sampled patients (36 of 450 were found to have evidence of comorbidities
on chart review). Conclusion. Results of this study suggest that eﬃcient queries/text searches of EMR data may provide reliable
data on comorbid conditions among cancer patients.
1.Background
Use of electronic medical records (EMRs) has grown dra-
matically over the last decade. Traditional methods for
identifying comorbidity data in EMRs for use in clinical
research have relied primarily on comprehensive manual
chart review. While highly sensitive for extracting data from
EMR systems, they are very costly and time consuming as
they need to be performed by trained chart abstractors [1].
The objective of the current study was to develop
and validate an eﬃcient and reliable algorithm to identify
comorbidities among advanced non-small cell lung cancer
(NSCLC) patients using relatively simple queries and text
ﬁeld searches of EMR data.
In 2010, cancer of the lung or bronchus resulted in
approximately 222,000 new cases and 167,000 deaths within
the United States [2]. Approximately 85% of lung cancer
patients will have NSCLC; most will have advanced stage
disease at the time of diagnosis, and 5-year survival is less
than 10% in this patient population [3, 4].
The median age of NSCLC patients is now slightly less
than 70 years [5], and 60% of cases occur in patients
≥65 years [6]. As a result, patients often present with
several concurrent comorbid conditions that may impair
organ function [7, 8] and result in reduced therapeutic
beneﬁt from chemotherapy [9]. In addition, common risk
factors for NSCLC, such as smoking or excessive alcohol2 Journal of Cancer Epidemiology
use [10], also place patients at greater risk for other serious
medical conditions such as heart disease, chronic obstructive
pulmonary disease (COPD), other cancers, and stroke.
ThepresenceofNSCLCtogetherwithaseriouscomorbid
condition has the potential to impact treatment decision
making and clinical outcomes [11]. Retrospective obser-
vational research on NSCLC outcomes using EMR data
should thus include information on patients’ comorbid
conditions, making the accurate and eﬃcient identiﬁcation
of comorbidity data vital. Information on adapting a clinical
comorbidity index for use with ICD-9-CM administrative
databases is available in the medical literature [1]. Lacking
in the literature is clarity on whether eﬃcient electronic
searches and queries of oncology EMR data can yield similar
comorbidity information in the absence of claims data and
without costly and lengthy manual chart abstraction.
2.Methods
2.1.Data Sources. This retrospective study utilizeddata from
US Oncology’s EMR system iKnowMed (iKM). iKM is an
oncology-speciﬁcEMRsystemthatcapturesoutpatientprac-
tice encounter history for patients under care including (but
notlimitedto)laboratory,diagnosis,therapyadministration,
line of therapy, staging, comorbidities, and performance
status information. This product is being implemented
across the US Oncology Comprehensive Strategic Alliance
(CSA) network. iKM currently is used by more than 900
community-basedoncologyproviders.Forthetime-frame of
this study, iKM was active in approximately 82% of the CSA
network.
Due to new initiatives to utilize an electronic medical
record system, US Oncology began to implement this elec-
tronic record early on in US Oncology’s history. Initially, the
EMRwasdesignedtocapturetheinformationthatwasprevi-
ously collected on the paper record. Currently, US Oncology
researchers have the ability to conduct retrospective studies
and gain access to the electronic data by submitting a
request to the US Oncology Institutional Review Board
(IRB). This current study was submitted to and approved
by the US Oncology IRB. There was minimal patient risk
related to this retrospective study, and patient conﬁdentiality
was rigorously maintained per US Oncology policies. Only
US Oncology employees on the study team had access to the
data and were involved in data manipulation and analysis.
Waiving informed consent did not adversely aﬀect patient
rights as they were unlikely to directly beneﬁt from this
study. Only the minimum number of variables necessary to
accomplishthegoalsofthisprojectwere extracted.Only data
thatfellwithinthestudytimeperiodwereusedandallresults
are reported in the aggregate. Electronic chart reviews were
conducted only for the purpose of validating data that were
abstracted through programmatic queries of the iKnowMed
database.
2.2. Patient Selection Criteria and Characteristics. As shown
in Figure 1, this study included advanced NSCLC patients
who initiated a ﬁrst- or second-line chemotherapy regimen
2,992 advanced NSCLC patients (ﬁrst- and
second-line) from full EMR receiving
chemotherapy from 7/1/2006–6/30/2008
2,812 without clinical trial
participation
2,663 without concurrent treatment
for another cancer
2,513 able to link to claims
data
Figure 1: Sample selection ﬂow chart. Abbreviations: EMR:
electronic medical record. NSCLC: non-small cell lung cancer.
in the 30-month period from July 1, 2006 through June 30,
2008. Patients in the 1st line cohort were not included in
the 2nd line cohort, even if they initiated 2nd line therapy
during the 30-month period. All patients received care at
a US Oncology Network practice utilizing iKM capabilities.
NSCLC disease was required to be Stage IIIB or IV or
recurrent (deﬁned as disease that was initially diagnosed as
early stage that progressed to metastatic disease). Patients
who were enrolled on formal IRB approved clinical trials
were excluded from this analysis as were any patients
receiving care for other primary cancers during the study
time period.
Phase 1: Algorithm for Identiﬁcation of Comorbidities . To
eﬃciently identify speciﬁc comorbid conditions, program-
matic queries were applied to standardized ﬁelds within
the EMR (i.e., concomitant illness tables, speciﬁc diagnosis
tables, review of symptoms, physical examination tables, and
pastmedicalhistorytable).Tosupplementtheprogrammatic
queries,keywordsearches(seetheappendix)wereconducted
of available text-based ﬁelds (e.g., dictation notes or nurse
progress notes). There were no time restrictions placed on
the queries or text ﬁeld searches meaning comorbidities
found at any time in the EMR were eligible.
Phase 2: Validation of Algorithm . We evaluated the reli-
ability of the EMR query/text ﬁeld search by comparing
comorbidity status of patients as identiﬁed via the query/text
ﬁeld search algorithm to the comorbidity status as identiﬁed
via the comprehensive chart review (the gold standard). To
do this, the algorithm was used to identify the patients in
the study sample without comorbidities. Seven groups of
patients were created by randomly sampling from among
these patients: one group (N = 150) had no evidence of
any comorbidities while 6 groups (N = 50 each) did not
have evidence of a single prespeciﬁed comorbidity. For all
patients in these 7 groups, comprehensive chart reviews (i.e.,
the gold standard) were conducted to verify that they were
trulynegative forcomorbidities.Reliability(asdemonstratedJournal of Cancer Epidemiology 3
by negative predictive value) of the algorithm was calculated
as follows:
Negative predictive value
=
True negatives

True negatives + False negatives
.
(1)
Negative predictive values greater than 80% were considered
to be acceptable. Negative predictive values greater than 90%
were considered to be good quality.
2.3. Statistics. Negative predictive values between speciﬁc
groups were compared using an exact version of Pearson’s
chi-square test. 95% conﬁdence intervals were calculated
using an exact test for proportions. All analyses were run in
SAS version 8.2 (Cary, North Carolina).
3.Results
3.1. Patient Disposition. Figure 1 summarizes the study pop-
ulation selection. During the study period, 2,992 patients
with advanced NSCLC received chemotherapy at a US
Oncology Network site that had iKM EMR capabilities. Of
these, 2,513 patients (84%) were included in this study.
Patient demographic and clinical characteristics as well as
comorbidity status (as documented via the EMR search
algorithm) are summarized in Table 1.
3.2. Concordance between Comprehensive Electronic Chart
Review and EMR Search Algorithm. The measured reliability
of the search algorithm is summarized in Table 2.O ft h e
150 patients randomly chosen who were negative for all
selected comorbidities via search algorithm, 16 were false
negatives (via “gold standard” comprehensive chart review),
for a negative predictive value of 89%. Within the 6 groups
of randomly selected patients (N = 50 each) who were
negative for speciﬁc comorbidities via search algorithm,
negative predictive values ranged from 82% for diabetes (9
of 50 patients were found to have diabetes on chart review)
to 100% for cerebrovascular disease and were found to diﬀer
signiﬁcantly in the six disease-speciﬁc samples (P = .007).
Considering the 450 patients from all groups, the overall
negative predictive value was 92% (36 of 450 were found to
have evidence of comorbidities on chart review).
4.Conclusions
Results of the current study suggest that eﬃcient pro-
grammatic queries and text ﬁeld searches of EMR data
may provide reliable data on comorbid conditions among
cancer patients. Among this population of advanced NSCLC
patients, the rate of comorbidities was 22%. The most
prevalent comorbidity, as expected, was COPD. This is
consistent with research in operable patients with NSCLC,
which has found rates of COPD as high as 50% [12].
Traditional methods for identifying comorbidity data in
EMRs for use in clinical research have relied primarily on
comprehensive manual chart review. While this study relied
Table 1: Patient characteristics of study sample (N = 2,513).
N (%)
Line of therapy
First-line 2004 (80%)
Second-line 509 (20%)
Age
Mean (SD) 69.7
Median (range) 70.7 (30–92)
Gender
Male 1378 (55%)
Female 1135 (45%)
Stage at diagnosis
I-IIIA 538 (24%)
IIIB-IV 1664 (76%)
Missing 311
Performance status
0 1045 (46%)
1 1032 (46%)
2+ 175 (8%)
Missing 261
Comorbidity status
Any comorbidity (1+ comorbidities) 553 (22%)
Speciﬁc comorbidities
Moderate/severe renal disease 37 (1.5%)
Congestive heart failure 106 (4.2%)
Chronic obstructive pulmonary disorder 218 (9%)
Cerebrovascular disease 33 (1.3%)
Diabetes 162 (6.4%)
Peripheral vascular disease 113 (4.5%)
Myocardial infarction 21 (0.8%)
Liver disease 16 (0.6%)
on chart reviews to be a highly sensitive gold standard for
extracting data from EMR systems, we also characterized
them as costly and time consuming as they were conducted
by nurses trained in chart abstraction over the course of
several weeks. As EMR data sources become more widely
utilized in health services and outcomes research, it will be
important to develop methods of electronically searching
the data in ways that are as clinically accurate but provide
signiﬁcant savings in both time and money compared to
manual chart reviews.
Using an algorithm that incorporated programmatic
queries and keyword searches of US Oncology’s cancer-
speciﬁc EMR system (iKM), we were able to reliably and
accurately identify comorbidities. In a validation study
using comprehensive electronic chart reviews, the algorithm
yielded an acceptable false negative rate (8%).
The beneﬁts of search algorithms of electronic records
compared with comprehensive manual chart reviews have
been previously reported [1, 13–15]. These include the
reduction in time and expense for data extraction as well
as the identiﬁcation of data in free-text chart notes that
otherwise would be diﬃcult to locate. While previous papers4 Journal of Cancer Epidemiology
Table 2: Measured reliability of algorithm (combinationof programmatic queries and key word searches).
Electronic chart review group True negatives
(via chart review)
False negatives
(via chart review)
Negative
predictive value
95% conﬁdence
interval
N = 450 patients identiﬁed as negative via
algorithm 414 36 0.92 0.89–0.94
Subgroup analyses of patients negative for comorbidities via algorithm
Group 1: Negative for all comorbidities
(N = 150) 134 16 0.89 0.83–0.94
Group 2: Negative for diabetes (N = 50) 41 9 0.82 0.69–0.91
Group 3: Negative for cardiovascular disease
(N = 50) 47 3 0.94 0.83–0.99
Group 4: Negative for cerebrovascular disease
(N = 50) 50 0 1.00 0.93–1.00
Group 5: Negative for moderate/severe renal
disease (N = 50) 47 3 0.94 0.83–0.99
Group 6: Negative for liver disease (N = 50) 49 1 0.95 0.89–0.99
Group 7: Negative for COPD (N = 50) 46 4 0.92 0.81–0.98
COPD: chronic obstructive pulmonary disorder.
have focused on the experience of single institutions, our
experience suggests that implementation within a large
oncology network is feasible. Reﬁnement of search algo-
rithms will continue to grow in importance as the use
of EMRs by the broader oncology community expands.
The lack of standard reporting requirements has been an
important limitation of attempts to use EMRs for clinical
research purposes [16]. The validity of the data extracted in
the current study reﬂects the strength of the iKM system in
terms of data standardization. Eﬀorts to improve the search
algorithm include ongoing collaborations by US Oncology
with their physicians to enhance and reﬁne the capture of
relevant free-text data and also to ensure the algorithm
reﬂects advances in the ﬁeld of oncology. US Oncology is
also working to improve iKM by deﬁning additional ﬁelds
their physicians need to capture and document the patients’
clinical information, as well as continuing to train their
physicians toenhancedocumentationanddatacapturerates.
While the use of oncology-speciﬁc EMR data and outpa-
tient claims data provides a very detailed and comprehensive
viewofthemedicaloncologysetting,alimitationofthestudy
is the likelihood of missing data on comorbidity-speciﬁc
resource utilization that may occur outside the US Oncol-
ogy network, particularly those associated with noncancer-
related events. Another limitation is that we studied only
t h en e g a t i v ep r e d i c t i v ev a l u eo ft h en e wa l g o r i t h m .T o
ascertain sensitivity would require a diﬀerent and potentially
arduous study design in which one captured suﬃciently
large numbers of patients with each of the comorbidities
via random selection from the population using the gold
standard manual chart review process. Our assumption
is that given the serious nature of the comorbidities of
interest, they were likely to have been reported to the
attending physician. It remains for future study whether the
comorbidities were subsequently properly captured in iKM.
Comorbidities as deﬁned in the current study relate to
physical conditions that are not a part of lung cancer, but
that may have an impact on treatment choices, safety, and
outcomes. The current search strategy using eﬃcient queries
of standardized EMR data may be widely applicable to other
oncology settings and research questions. The current report
suggests it is possible toextract research data in a reliableand
timely manner.
Appendix
iKMSearchTermsUsed inThisStudy
DM: Diabetes mellitus
Congestive heart failure
Peripheral vascular disease
Aortic aneurysm
Aortic dissection
Thoracic aneurysm
Abdominal aneurysm
Venous thromboembolism
Myocardial infarction
Coronary artery disease
CAD
HTN
Cereb
Hemorrhage
Cranial
Occlusion
Embolism
Obstruction
Stroke
Thrombosis
NarrowingJournal of Cancer Epidemiology 5
Transient
TCI
CVA
TIA
Chronic glomerulonephritis
Nephritis
Nephropathy
Kidney
Renal failure
CRI
Cirrhosis
Hepatitis
Portal
Liver
Hepatic
Hepatorenal
Varices
CPD
COPD
Chronic and pulmonary
Bronchitis.
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